Table 1. BCR/ABLp210 CSCs follow the CSC model, while BCR/ABLp185 CSCs progress through frequent leukaemic clones
BCR/ABLp210
Leukaemia incidenceCell dose
1,000,000100,00010,0001,000100
Case 120/20
Case 222/31
Case 31/20/30/40/4
BCR/ABLp185
Leukaemia incidenceCell dose
250,000100,00050,00010,0001,0001005010
Case 15/5
Case 27/75/52/22/2
Case 35/55/52/23/62/7
  • In vivo limiting dilution assay of serially transplanted BCR/ABLp210 and BCR/ABLp185 leukaemia. Whole GFP+ leukaemic cells were FACS‐sorted from moribund primary transplanted mice and injected into NOD/SCID/IL‐2Rγ−/− mice in indicated dilutions.